I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference

I-Mab 將參加第 23 屆年度 Needham 虛擬醫療會議

天境生物 · 04/05 12:00

ROCKVILLE, Md., April 5, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that management will present at the 23^rd Annual Needham Virtual Healthcare Conference on April 11, 2024.

馬里蘭州羅克維爾，2024年4月5日 /PRNewswire/ — 總部位於美國的全球生物技術公司I-Mab（納斯達克股票代碼：IMAB）今天宣佈，管理層將出席第二十三屆會議，該公司專門研究治療癌症的高差異化免疫療法的開發和潛在商業化^第三方 2024 年 4 月 11 日舉行的年度尼德姆虛擬醫療保健會議。

23^rd Annual Needham Virtual Healthcare Conference

23^第三方年度 Needham 虛擬醫療會議

Presentation Time	Thursday, April 11 at 10:15 a.m. EST
Presenters	Raj Kannan, CEO; John Hayslip CMO
Webcast link	Here
Meetings	One-on-one and small group meetings: April 11, 2024
Management Participants	Raj Kannan, CEO Joe Skelton, CFO John Hayslip, CMO Tyler Ehler, Senior Director, Investor Relations

演示時間	美國東部標準時間4月11日星期四上午10點15分
演示者	首席執行官拉吉·坎南；約翰·海斯利普首席營銷官
網絡直播鏈接	這裏
會議	一對一和小組會議：2024 年 4 月 11 日
管理參與者	首席執行官拉吉·坎南首席財務官喬·斯凱爾頓首席營銷官約翰·海斯利普泰勒·埃勒，投資者關係高級董事

The webcast will also be available under "Event Calendar" on I-Mab's IR website
at http://ir.i-mabbiopharma.com/

網絡直播還將在 I-Mab 投資者關係網站上的 “活動日曆” 下播出
在 http://ir.i-mabbiopharma.com/

For more information, please contact your Needham representative.

欲了解更多信息，請聯繫您的 Needham 代表。

About I-Mab

關於 i-Mab

I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer. I-Mab has established operations in Rockville, Maryland, and in San Diego, California. For more information, please visit http://www.i-mabbiopharma.com and follow us on LinkedIn and X.

I-Mab（納斯達克股票代碼：IMAB）是一家總部位於美國的全球生物技術公司，專門致力於治療癌症的高差異化免疫療法的開發和潛在商業化。I-Mab 已在馬里蘭州羅克維爾和加利福尼亞州聖地亞哥開展業務。欲了解更多信息，請訪問 http://www.i-mabbiopharma.com 然後在 LinkedIn 和 X 上關注我們。

For more information, please contact:
Tyler Ehler
Senior Director, Investor Relations
IR@imabbio.com

欲了解更多信息，請聯繫：
泰勒·埃勒
投資者關係高級董事
IR@imabbio.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/i-mab-to-participate-at-the-23rd-annual-needham-virtual-healthcare-conference-302108935.html

查看原創內容以下載多媒體：https://www.prnewswire.com/news-releases/i-mab-to-participate-at-the-23rd-annual-needham-virtual-healthcare-conference-302108935.html

SOURCE I-Mab Biopharma

來源 I-Mab Biopharma

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。

I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference

I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference

風險及免責聲明

聲明